Pneumonia Testing Market Size 2024-2028

The pneumonia testing market size is forecast to increase by USD 807.5 million at a CAGR of 5.69% between 2023 and 2028. The market's expansion is driven by several factors, notably the increasing prevalence of pneumonia and heightened mortality concerns associated with the disease, advancements in multiplex PCR technology enabling more accurate pneumonia detection, and the expanding elderly population. However, challenges such as inadequate healthcare infrastructure in developing nations, a shortage of skilled healthcare professionals, and stringent governmental regulations present hurdles to market growth. Despite these obstacles, the demand for effective pneumonia detection and treatment solutions continues to rise, driven by the pressing need to address the healthcare burden posed by this respiratory condition. Addressing these challenges requires collaborative efforts from stakeholders to improve healthcare infrastructure, enhance workforce capacity, and navigate regulatory landscapes. By overcoming these obstacles, the market can unlock its full potential and meet the growing demand for pneumonia management solutions worldwide.

It also includes an in-depth analysis of market trends and analysis, market growth analysis and challenges. Furthermore, the report includes historic market data from 2018 - 2022.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, View Report Sample

Market Dynamics and Customer Landscape

The market addresses the pressing need for accurate diagnosis and treatment. Traditional methods like cultures face challenges due to their time-consuming process and error rates. Point-of-care (POC) testing, including enzyme-linked immunosorbent assay (ELISA) and immunofluorescence, offer rapid results. With sedentary lifestyles and environmental factors contributing to the prevalence, technologies like Curetis Unyvero System and GE Healthcare's Thoracic Care Suite provide advanced solutions. Collaboration with contract research organizations (CROs) aligns with ATS, IDSA, and CAP guidelines for improved reimbursements and effective antifungal treatment against Streptococcus pneumonia. Our researchers analyzed the data with 2023 as the base year and the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Market Driver

The market is experiencing notable growth driven by the escalating prevalence of pneumonia and the associated concerns regarding mortality rates. A significant surge in pneumonia cases globally is expected to fuel the demand for advanced diagnostic solutions. Pneumonia, particularly prevalent among children and the elderly, remains a leading cause of hospitalization worldwide. For instance, according to data released by the United Nations International Children's Emergency Fund (UNICEF), there were approximately 1,400 cases per 100,000 individuals globally in 2020 alone. Consequently, factors like these play pivotal roles in propelling market growth.

Furthermore, it is recognized as a leading cause of hospitalization among infectious diseases, prompting critical care and further microbiological testing for accurate diagnosis. The burden of poverty-related factors such as malnutrition, inadequate access to safe drinking water and sanitation, and exposure to air pollution contributes significantly to pneumonia-related mortality in low-resource settings. As a response to the escalating mortality rates, governments in developing countries are initiating efforts to enhance diagnostic awareness to prevent avoidable deaths. Consequently, these factors are anticipated to drive significant growth of the market research during the forecast period.

Significant Market Trends

The rising number of M&A and new product launches are emerging trends in the market. The new product additions will motivate consumers to purchase various pneumonia-testing products. Furthermore, the increasing number of product launches and M&A also increases the competition in the market, which, in turn, will lead to innovation and differentiation. The market for advanced diagnostic products faces unique challenges due to the complex nature of the diseases caused by pathogens such as Streptococcus, Legionella, Chlamydophilla, and Mycoplasma. Mortality rates associated with acute lung infections, including pneumonia, are significant, highlighting the importance of accurate and timely diagnoses.

However, health awareness and marketing efforts play a limited role in this niche market. Instead, vendors focus on expanding distribution networks and increasing product availability to end-users. Infectious diseases like pneumonia, caused by various pathogens, can be challenging to diagnose due to the difficulty in obtaining respiratory tract specimens and the presence of false positive results, superinfections, and medication complications. Point-of-care diagnostics, such as microscopy, culture, blood cultures, antigen detection, serology, and sensor technologies, are essential for accurate diagnoses. Hence, such partnerships are expected to fuel the growth of the market in focus during the forecast period.

Major Market Challenge

The lack of trained professionals is a major challenge impeding the market growth. Effective translation of diagnostics from research to application results in the correct diagnosis of diseases. Diagnosis of diseases requires extensive analysis to interpret the correct results. Therefore, clinical laboratories require trained specialists in this field. However, the presence of these specialists is scarce in diagnostic centers and hospitals worldwide. The global market is significant due to the high prevalence of acute lung infections caused by various pathogens such as Streptococcus, Legionella, Chlamydophilla, and Mycoplasma.

Additionally, most rural hospitals across the world face issues such as the lack of patient volume required to justify having specialists. Furthermore, appointments of in-house specialists are cost-prohibitive, especially for small medical facilities. Limited public funds, the allocation of a small portion of this funding to laboratories, and an even smaller portion being allocated for quality assurance are some of the reasons for the lack of specialists in many developing countries. Therefore, end-users such as hospitals and diagnostic centers need to invest heavily to increase the number of trained professionals by providing training to their employees. This training and hiring of professionals increase the cost, which in turn, will hinder the market growth and trends during the forecast period.

Key Market Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth and forecasting strategies.

Market Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Pfizer Inc.- The company is engaged in the discovery, development, manufacturing, marketing, sales, and distribution of biopharmaceutical products worldwide. 

The research report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

• Abbott Laboratories
• Acumen Diagnostics Pte Ltd.
• Becton Dickinson and Co.
• bioMerieux SA
• Bio Rad Laboratories Inc.
• Danaher Corp.
• Diamedica SIA
• DiaSorin SpA
• F. Hoffmann La Roche Ltd.
• Hologic Inc.
• Laboratory Corp. of America Holdings
• LGC Science Group Holdings Ltd.
• Meridian Bioscience Inc.
• OpGen Inc.
• Pfizer Inc.
• Quest Diagnostics Inc.
• Quidelortho Corp.
• Siemens AG
• Thermo Fisher Scientific Inc.
• Trinity Biotech Plc

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Segmentation 

The market is evolving to meet the needs of an aging population and rising healthcare costs. While traditional methods like cultures have drawbacks such as error rates, antifungals, and point-of-care (POC) testing offer promising alternatives. Advanced systems like the Unyvero System and LRT Cartridge from GE Healthcare streamline pneumonia diagnostics, particularly against Streptococcus pneumoniae. Addressing factors like unhealthy food habits, this market strives to enhance geriatric care and optimize healthcare expenditure.

By Product Type

The market share growth by the consumables segment will be significant during the forecast period. The consumables used for the detection of pneumonia contamination include kits and reagents such as PCR assays, nucleic acid detection kits, staining materials, elimination kits and reagents, standards, and controls.

Get a glance at the market contribution of various segments View the PDF Sample

The consumables segment was valued at USD 1.12 billion in 2018. The industry encompasses diagnostic methods for identifying microbial pathogens causing pneumonia. Immunodiagnostics, utilizing antibodies and antigens, plays a significant role, offering advantages such as high sensitivity and specificity. Key applications include infectious diseases in children and geriatric populations. Nucleic acid detection methods, like Polymerase Chain Reaction (PCR), are also essential. Antibiotics and antifungal treatment rely on accurate diagnostics.  Hence, the increasing focus of companies on developing consumables such as kits and reagents used for detection and the adoption of these consumables by various end-users are expected to positively impact the growth of the market during the forecast period. 

By Region

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 31% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

North America is a dominating region in the global market, with the US and Canada as the leading revenue-generating countries. Increasing demand for timely and accurate diagnosis of lung infections and other infectious diseases and the presence of several pharmaceutical companies that are focusing on drug development is driving the adoption of testing in the region. Moreover, several big pharmaceutical companies, such as bioMerieux, Pfizer, Roche, and several others, are researching to develop drugs and produce vaccines, which, in turn, has increased the demand for tests for drug screening and other purposes. For instance, in 2021, Pfizer announced to receive approval from FDA for PREVNAR, 20 Pfizer's pneumococcal 20-valent conjugate vaccine for adults ages 18 years or older. Such developments and approvals are expected to drive the market growth of the regional market during the forecast period.

In addition, R&D investments have increased in the region.  This resulted in the increased production of pharmaceutical products such as drugs, vaccines, and antibodies for the treatment of people suffering from various diseases, in turn, increasing the demand for tests to monitor the production of such products. Furthermore, the pharmaceutical industry is growing in the region due to the need for drug discovery and is expected to reach USD 1 trillion by the end of 2023 due to the emergence of several fatal diseases, and rising demand for personalized medicine. The increasing emphasis on drug production will drive the growth of the market in North America during the forecast period.

Segment Overview

The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

• Product Type Outlook 
  • Consumables
  • Analyzers
• Method Outlook 
  • Immunodiagnostics
  • Molecular diagnostics
  • Point-of-care testing
• Region Outlook 
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
    • Others
  • Rest of World
    • Saudi Arabia
    • South Africa
    • Brazil
    • Others

Market Analyst Overview 

In the realm of pneumonia testing, point of care (POC) testing is gaining prominence, especially among the geriatric population. Unlike the traditional method reliant on cultures, POC testing offers advantages like rapid results and lower error rates. The pneumonia testing industry emphasizes early detection to mitigate the morbidity and fatality rates associated with lung infections. Molecular diagnostic assays play a pivotal role in identifying pathogens like Streptococcus, contributing to more targeted treatment approaches. However, diagnosing pneumonia, whether viral or bacterial, presents challenges, leading to efforts by institutions like the Massachusetts Institute of Technology to develop rapid molecular diagnostic testing. Enhanced healthcare awareness and favorable reimbursement policies further encourage preventive care strategies, particularly crucial for individuals with chronic diseases.

Further, in the domain of bronchiectasis drugs, addressing the challenge of difficulty in diagnosing remains paramount. The traditional method involving cultures is plagued by its inherent error rate, necessitating more precise diagnostic tools. Bronchiectasis, a chronic medical condition characterized by lung infection and damage to the alveoli, poses significant morbidity and mortality rates, as highlighted by organizations like the World Health Organization. Differentiating between viral pneumonia and bacterial pneumonia is crucial, given their distinct treatment approaches. Physician approaches often rely on immunoassay techniques to identify pathogens like Streptococcus, a key aspect of the in vitro diagnostics market. Additionally, superinfections and the role of the microbiome in exacerbating acute lung infections underscore the need for targeted therapeutic interventions.

View PDF Sample

What are the Key Data Covered in this Market Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2024 and 2028
• Precise estimation of the size of the market size and its contribution to the parent market
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. 

Get in touch